Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suvemcitug - Simcere Pharmaceutical Group

Next Previous
Drug Profile

Suvemcitug - Simcere Pharmaceutical Group

Alternative Names: Anti-VEGF monoclonal antibody - Pyxis Oncology; APX-003; BD-0801; EP-10030; Sevacizumab - Pyxis Oncology; SIM-BD-0801

Latest Information Update: 23 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epitomics
  • Developer Jiangsu T-mab BioPharma; Simcere Pharmaceutical Group
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Colorectal cancer; Solid tumours
  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 02 Jun 2024 Efficacy and adverse event data from the phase phase III SCORES trial in Ovarian cancer released by Simcere Pharmaceutical
  • 31 May 2024 Efficacy and adverse event data from the phase III SCORES trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 13 Mar 2024 Jiangsu Simcere Pharmaceutical terminated a phase II trial in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (SC), due to the sponsor's research and development strategy adjustment (NCT05148195)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top